CD274 and non-small cell lung carcinoma: The correlation between MIB2 and sensitivity to PD-1 mAb therapy was evaluated in a separate cohort of 31 patients with NSCLC who underwent needle biopsy before nivolumab treatment as first-line therapy, regardless of the PD-L1 status (Supplemental Table 3).